Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 117Carcinoma, Non-Small-Cell Lung 102Carcinoma, Renal Cell 69Colorectal Neoplasms 46Neoplasm Metastasis 41Squamous Cell Carcinoma of Head and Neck 39Carcinoma, Hepatocellular 38Neoplasms 36Lung Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 22Carcinoma, Transitional Cell 21Hodgkin Disease 20Brain Neoplasms 20Pancreatic Neoplasms 18Ovarian Neoplasms 18Prostatic Neoplasms 17Head and Neck Neoplasms 16Colonic Neoplasms 16Skin Neoplasms 15Triple Negative Breast Neoplasms 14Sarcoma 14Glioblastoma 14Adenocarcinoma Of Esophagus 14Carcinoma, Merkel Cell 13Small Cell Lung Carcinoma 12Rectal Neoplasms 12Esophageal Neoplasms 12Breast Neoplasms 12Uveal Melanoma 11

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Nivolumab × 1 year × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡